Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

SANASana Biotechnology, Inc.

Nasdaq · CIK 0001770121
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts220

Identity from submissions API

NameSana Biotechnology, Inc.
CIK0001770121
TickersSANA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN831381173
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(206) 701-7914
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
188 EAST BLAINE STREET, SUITE 350
SEATTLE
WA
WA
Mailing address
188 EAST BLAINE STREET, SUITE 350
SEATTLE
WA
WA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

392 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-05 10-Q 10-Q 0001193125-26-449836 001-39941 261527425 34 13313599 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-449791 001-39941 261527274 34 581158 1 1
2026-11-05 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002831 005-92124 261526293 34 11597
2026-10-06 4 PRIMARY DOCUMENT 0001480212-26-000010 4975
2026-09-08 8-K 8-K 7.01,9.01 0001193125-26-384405 001-39941 261363424 34 3636161 1 1
2026-08-27 4 PRIMARY DOCUMENT 0002115339-26-000004 9140
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001012975-26-000773 005-92124 261281156 34 30696
2026-08-10 10-Q 10-Q 0001193125-26-342395 001-39941 261258527 34 12065105 1 1
2026-08-10 8-K 8-K 2.02,9.01 0001193125-26-342371 001-39941 261258469 34 541162 1 1
2026-07-07 4 PRIMARY DOCUMENT 0001480212-26-000008 4975
2026-06-05 4 PRIMARY DOCUMENT 0001309988-26-000002 9462
2026-06-05 4 PRIMARY DOCUMENT 0001645041-26-000002 9478
2026-06-05 4 PRIMARY DOCUMENT 0001836301-26-000014 9460
2026-06-05 4 PRIMARY DOCUMENT 0001757533-26-000011 9484
2026-06-05 4 PRIMARY DOCUMENT 0001376247-26-000002 9473
2026-06-05 4 PRIMARY DOCUMENT 0001480212-26-000006 5854
2026-06-05 4 PRIMARY DOCUMENT 0001612312-26-000002 9479
2026-06-05 4 PRIMARY DOCUMENT 0001770121-26-000003 9210
2026-06-05 8-K 8-K 5.07 0001193125-26-259532 001-39941 261069039 34 183089 1 1
2026-05-21 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000166 005-92124 261010567 34 19057
2026-05-15 8-K 8-K 8.01 0001193125-26-226674 001-39941 26987157 34 139649 1 1
2026-05-11 S-8 S-8 0001193125-26-216824 333-295758 26963456 33 198237 1 1
2026-05-11 10-Q 10-Q 0001193125-26-216769 001-39941 26963272 34 10552674 1 1
2026-05-11 8-K 8-K 2.02,9.01 0001193125-26-216758 001-39941 26963228 34 431226 1 1
2026-04-24 ARS ARS 0001193125-26-174895 001-39941 26890391 34 3002006
2026-04-24 DEFA14A DEFA14A 0001193125-26-174886 001-39941 26890384 34 566529
2026-04-24 DEF 14A DEF 14A 0001193125-26-174883 001-39941 26890381 34 2711271 1 1
2026-04-24 8-K 8-K 5.02 0001193125-26-174531 001-39941 26890295 34 190110 1 1
2026-04-13 424B5 424B5 0001193125-26-153046 333-293981 26858438 33 560319 1 1
2026-04-13 8-K 8-K 8.01,9.01 0001193125-26-152868 001-39941 26857911 34 561784 1 1
2026-04-08 4 PRIMARY DOCUMENT 0001480212-26-000004 4974
2026-03-27 3 PRIMARY DOCUMENT 0002115339-26-000002 15933
2026-03-10 4 PRIMARY DOCUMENT 0001627387-26-000004 16887
2026-03-10 4 PRIMARY DOCUMENT 0001568605-26-000008 14458
2026-03-06 4 PRIMARY DOCUMENT 0001568605-26-000006 8358
2026-03-06 4 PRIMARY DOCUMENT 0001627387-26-000002 8295
2026-03-04 4 PRIMARY DOCUMENT 0001568605-26-000004 8920
2026-03-03 S-3ASR S-3ASR 0001193125-26-088784 333-293981 26716581 33 994208 1 1
2026-03-03 10-K 10-K 0001193125-26-088215 001-39941 26714284 34 49981942 1 1
2026-03-03 8-K 8-K 2.02,8.01,9.01 0001193125-26-088203 001-39941 26714181 34 1100839 1 1
2026-02-18 4 PRIMARY DOCUMENT 0001665924-26-000008 8343
2026-02-18 3 PRIMARY DOCUMENT 0001665924-26-000007 6749
2026-02-17 8-K 8-K 5.02,7.01,9.01 0001193125-26-053294 001-39941 26636971 34 346722 1 1
2026-01-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-26-000786 005-92124 26545993 34 10836
2026-01-14 8-K 8-K 7.01,9.01 0001193125-26-012664 001-39941 26532380 34 13069830 1 1
2026-01-06 4 PRIMARY DOCUMENT 0001480212-26-000002 8428
2026-01-06 4 PRIMARY DOCUMENT 0001568605-26-000002 8755
2025-12-16 4 PRIMARY DOCUMENT 0001568605-25-000007 8701
2025-12-05 4 PRIMARY DOCUMENT 0001568605-25-000005 22905
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001012975-25-000773 005-92124 251487026 34 30908
2025-11-06 10-Q 10-Q 0001193125-25-269569 001-39941 251458500 34 11495786 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-269522 001-39941 251458367 34 538733 1 1
2025-10-07 4 PRIMARY DOCUMENT 0001480212-25-000006 4869
2025-09-10 UPLOAD filename1.pdf 0000000000-25-009796 001-39941 39819
2025-09-05 8-K 8-K 5.02,8.01 0001193125-25-196414 001-39941 251294925 34 168531 1 1
2025-08-29 8-K 8-K 5.02 0001193125-25-192766 001-39941 251280973 34 164664 1 1
2025-08-13 CORRESP filename1.htm 0001193125-25-179835 26543
2025-08-11 10-Q 10-Q 0001770121-25-000010 001-39941 251202095 34 11133417 1 1
2025-08-11 8-K 8-K 2.02,9.01 0001770121-25-000009 001-39941 251202061 34 523512 1 1
2025-08-07 8-K 8-K 1.01,8.01,9.01 0001193125-25-175571 001-39941 251195288 34 547218 1 1
2025-08-07 424B5 424B5 0001193125-25-175493 333-277584 251194815 33 679750
2025-08-06 424B5 424B5 0001193125-25-174567 333-277584 251190632 33 680892
2025-08-06 8-K 8-K 2.02,8.01 0001193125-25-174506 001-39941 251190157 34 153490 1 1
2025-07-30 UPLOAD filename1.pdf 0000000000-25-007978 001-39941 47023
2025-07-08 4 PRIMARY DOCUMENT 0001562180-25-005349 4869
2025-06-23 8-K 8-K 8.01,9.01 0000950170-25-088752 001-39941 251063317 34 212226 1 1
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004647 5641
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004646 5775
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004645 5728
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004644 5763
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004643 5740
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004642 5734
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004641 5769
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004640 5825
2025-06-09 4 PRIMARY DOCUMENT 0001562180-25-004639 5783
2025-06-09 3 PRIMARY DOCUMENT 0001562180-25-004638 6780
2025-06-06 8-K 8-K 5.07 0000950170-25-083044 001-39941 251030530 34 185743 1 1
2025-05-08 424B5 424B5 0001193125-25-116035 333-277584 25927024 33 628055
2025-05-08 S-8 S-8 0001193125-25-116015 333-287088 25926848 33 82027
2025-05-08 10-Q 10-Q 0000950170-25-066943 001-39941 25926121 34 10389734 1 1
2025-05-08 8-K 8-K 2.02,8.01,9.01 0000950170-25-066933 001-39941 25926040 34 1395185 1 1
2025-04-25 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001704 005-92124 25871751 34 11154
2025-04-25 ARS ARS 0001193125-25-094675 001-39941 25869778 34 2980809
2025-04-25 DEFA14A DEFA14A 0001193125-25-094670 001-39941 25869770 34 493964
2025-04-25 DEF 14A DEF 14A 0001193125-25-094656 001-39941 25869753 34 2768666 1 1
2025-04-08 4 PRIMARY DOCUMENT 0001562180-25-003066 4849
2025-03-21 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000728 333-277584 25762106 33 1769
2025-03-17 POS AM POS AM 0001193125-25-055657 333-277584 25745116 33 384064
2025-03-17 10-K 10-K 0000950170-25-040254 001-39941 25744544 34 47111271 1 1
2025-03-17 8-K 8-K 2.02,9.01 0000950170-25-040241 001-39941 25744468 34 645756 1 1
2025-03-14 POSASR POSASR 0001193125-25-054813 333-277584 25740255 33 461025
2025-03-10 4 PRIMARY DOCUMENT 0001562180-25-002274 13893
2025-03-10 4 PRIMARY DOCUMENT 0001562180-25-002273 14123
2025-03-10 4 PRIMARY DOCUMENT 0001562180-25-002271 16302
2025-03-03 4 PRIMARY DOCUMENT 0001562180-25-001888 8957
2025-02-18 144 xsl144X01/primary_doc.xml 0001950047-25-000950 001-39941 25635325 33 6302
2025-01-31 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000210 005-92124 25576313 34 6268
2025-01-16 144 xsl144X01/primary_doc.xml 0001950047-25-000291 001-39941 25536016 33 5556
2025-01-13 8-K 8-K 7.01,9.01 0001193125-25-005047 001-39941 25525046 34 15160031 1 1
2025-01-10 4 4 0000950170-25-004052 13090
2025-01-07 4 PRIMARY DOCUMENT 0001562180-25-000238 4848
2025-01-03 4 PRIMARY DOCUMENT 0001562180-25-000105 9130
2024-12-16 144 xsl144X01/primary_doc.xml 0001950047-24-009879 001-39941 241552305 33 4818
2024-11-26 144 xsl144X01/primary_doc.xml 0001963745-24-000051 001-39941 241505785 33 5547
2024-11-25 144 xsl144X01/primary_doc.xml 0001950047-24-009115 001-39941 241497431 33 5512
2024-11-21 3/A 3/A 0000950170-24-129613 5546
2024-11-14 SC 13G/A ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G/A(#3) 0001072613-24-000883 005-92124 241464226 34 476073
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-117983 005-92124 241456702 34 62619
2024-11-12 SC 13G/A UnitedStates_13G__SanaBiotec.txt 0000932471-24-001160 005-92124 241449417 34 6570
2024-11-12 SC 13G/A filing.txt 0000315066-24-002853 005-92124 241444948 34 8056
2024-11-08 SC 13G us7995661045_110824.txt 0002012383-24-003529 005-92124 241439671 34 13946
2024-11-08 10-Q 10-Q 0000950170-24-123730 001-39941 241438204 34 10754890 1 1
2024-11-08 8-K 8-K 2.02,9.01 0000950170-24-123727 001-39941 241438190 34 493917 1 1
2024-11-04 SC 13G/A UnitedStates_13G__SanaBiotec.txt 0000932471-24-000757 005-92124 241422576 34 5615
2024-10-22 SC 13G us7995661045_102224.txt 0002012383-24-001603 005-92124 241387311 34 13932
2024-10-21 144 xsl144X01/primary_doc.xml 0001950047-24-007830 001-39941 241384202 33 4745
2024-10-15 3 PRIMARY DOCUMENT 0001562180-24-007331 18500
2024-10-09 4 PRIMARY DOCUMENT 0001562180-24-007283 4848
2024-10-08 8-K 8-K 5.02 0000950170-24-113524 001-39941 241360361 34 180621 1 1
2024-09-26 4 PRIMARY DOCUMENT 0001562180-24-006954 7566
2024-09-25 144 xsl144X01/primary_doc.xml 0001950047-24-007386 001-39941 241324487 33 5517
2024-09-24 144 xsl144X01/primary_doc.xml 0001950047-24-007370 001-39941 241320472 33 4791
2024-09-12 8-K 8-K 5.02 0001193125-24-218049 001-39941 241295425 34 146640 1 1
2024-08-08 10-Q 10-Q 0000950170-24-094052 001-39941 241188750 34 10706232 1 1
2024-08-08 8-K 8-K 2.02,9.01 0000950170-24-093976 001-39941 241188452 34 436163 1 1
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005724 6132
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005723 6112
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005722 6083
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005721 6177
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005720 6118
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005719 6089
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005718 6097
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005716 6077
2024-07-15 4/A PRIMARY DOCUMENT 0001562180-24-005715 6124
2024-07-08 4 PRIMARY DOCUMENT 0001562180-24-005643 4848
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004845 5762
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004844 5733
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004843 5827
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004842 5768
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004841 5739
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004840 5747
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004839 9585
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004838 5774
2024-06-07 4 PRIMARY DOCUMENT 0001562180-24-004837 5782
2024-06-07 8-K 8-K 5.07 0000950170-24-070603 001-39941 241029277 34 182843 1 1
2024-05-08 S-8 S-8 0001193125-24-134294 333-279219 24927074 33 298253
2024-05-08 10-Q 10-Q 0000950170-24-055727 001-39941 24926525 34 10133928 1 1
2024-05-08 8-K 8-K 2.02,9.01 0000950170-24-055673 001-39941 24926224 34 364854 1 1
2024-04-26 ARS ARS 0001193125-24-115460 001-39941 24878448 34 3155058
2024-04-26 DEFA14A DEFA14A 0001193125-24-115456 001-39941 24878439 34 343214
2024-04-26 DEF 14A DEF 14A 0001193125-24-115454 001-39941 24878432 34 1095080
2024-04-18 8-K 8-K 5.02 0001193125-24-100902 001-39941 24854933 34 145478 1 1
2024-04-08 4 PRIMARY DOCUMENT 0001562180-24-003354 4847
2024-04-08 3 3 0000950170-24-042434 5651
2024-04-03 SC 13G/A filing.txt 0000315066-24-001687 005-92124 24817144 34 7628
2024-03-11 4 PRIMARY DOCUMENT 0001562180-24-002538 5335
2024-03-08 4 PRIMARY DOCUMENT 0001562180-24-002480 8369
2024-03-08 4 PRIMARY DOCUMENT 0001562180-24-002479 8313
2024-03-08 4 PRIMARY DOCUMENT 0001562180-24-002477 8376
2024-03-08 4 PRIMARY DOCUMENT 0001562180-24-002476 8368
2024-03-08 4 PRIMARY DOCUMENT 0001562180-24-002474 8376
2024-03-07 SC 13G/A sanabiotechnology29022024.txt 0001088875-24-000063 005-92124 24728123 34 10788
2024-03-01 S-3ASR S-3ASR 0001193125-24-055908 333-277584 24709696 33 1050218
2024-02-29 10-K 10-K 0000950170-24-023119 001-39941 24703992 34 59267067 1 1
2024-02-29 8-K 8-K 2.02,9.01 0000950170-24-023083 001-39941 24703737 34 567595 1 1
2024-02-14 SC 13G/A SC 13G/A 0001193125-24-036260 005-92124 24638631 34 155159
2024-02-14 4 4 0000950170-24-015185 7989
2024-02-14 3 3 0000950170-24-015184 7715
2024-02-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-002842 13191
2024-02-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-002841 15624
2024-02-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-002840 27431
2024-02-09 SC 13G/A ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G/A(#2) 0001072613-24-000117 005-92124 24616365 34 475594
2024-02-09 SC 13G/A filing.txt 0000315066-24-001443 005-92124 24612086 34 7833
2024-02-08 8-K 8-K 1.01,8.01,9.01 0001193125-24-028506 001-39941 24610221 34 550475 1 1
2024-02-08 424B5 424B5 0001193125-24-028442 333-266547 24609836 33 1137873
2024-02-08 FWP FWP 0001193125-24-027181 333-266547 24606666 34 100037
2024-02-07 424B5 424B5 0001193125-24-026790 333-266547 24605120 33 1040740
2024-02-07 8-K 8-K 2.02,8.01,9.01 0001193125-24-026692 001-39941 24604418 34 220763 1 1
2024-01-26 SC 13G/A sanabiotechnology29122023.txt 0001088875-24-000012 005-92124 24564090 34 11226
2024-01-09 8-K 8-K 7.01,9.01 0001193125-24-004910 001-39941 24521899 34 4666115 1 1
2024-01-08 4 PRIMARY DOCUMENT 0001562180-24-000342 8705
2024-01-08 4 PRIMARY DOCUMENT 0001562180-24-000341 8812
2023-12-18 4 PRIMARY DOCUMENT 0001562180-23-008445 9446
2023-12-15 144 xsl144X01/primary_doc.xml 0001950047-23-006163 001-39941 231490884 33 4743
2023-12-11 8-K 8-K 7.01,9.01 0001193125-23-292542 001-39941 231478098 34 4006156 1 1
2023-11-08 10-Q 10-Q 0000950170-23-061171 001-39941 231388255 34 13956120 1 1
2023-11-08 8-K 8-K 2.02,9.01 0000950170-23-061130 001-39941 231388033 34 614998 1 1
2023-11-03 4 PRIMARY DOCUMENT 0001562180-23-007553 5769
2023-11-03 4 PRIMARY DOCUMENT 0001562180-23-007550 5776
2023-11-03 4 PRIMARY DOCUMENT 0001562180-23-007547 5768
2023-10-10 8-K 8-K 2.05,7.01,9.01 0001193125-23-253493 001-39941 231318254 34 3945908 1 1
2023-10-06 4 PRIMARY DOCUMENT 0001562180-23-007237 4863
2023-10-06 4 PRIMARY DOCUMENT 0001562180-23-007236 4933
2023-09-15 4 FORM 4 SUBMISSION 0000899243-23-019165 32698
2023-09-13 8-K 8-K 7.01,9.01 0000950170-23-047822 001-39941 231251556 34 27433098 1 1
2023-08-21 8-K 8-K 1.02 0000950170-23-043683 001-39941 231189156 34 189187 1 1
2023-08-03 10-Q 10-Q 0000950170-23-038050 001-39941 231140438 34 13782979 1 1
2023-08-03 8-K 8-K 2.02,9.01 0000950170-23-038002 001-39941 231140187 34 680620 1 1
2023-07-06 4 PRIMARY DOCUMENT 0001562180-23-005766 4863
2023-07-06 4 PRIMARY DOCUMENT 0001562180-23-005765 4933
2023-06-12 4 PRIMARY DOCUMENT 0001562180-23-005089 9458
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005031 9468
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005030 9516
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005029 9494
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005028 5662
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005027 9475
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005026 9518
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005025 5562
2023-06-09 8-K 8-K 5.07 0000950170-23-027254 001-39941 231005244 34 208647 1 1
2023-06-08 4 FORM 4 SUBMISSION 0000899243-23-014953 19402
2023-06-07 144 xsl144X01/primary_doc.xml 0001968582-23-000210 001-39941 23999123 33 6914
2023-06-07 144 xsl144X01/primary_doc.xml 0001968582-23-000209 001-39941 23999073 33 6891
2023-06-07 8-K 8-K 7.01,9.01 0000950170-23-026732 001-39941 23997578 34 14010365 1 1
2023-05-26 4 FORM 4 SUBMISSION 0000899243-23-013992 23363
2023-05-24 144 xsl144X01/primary_doc.xml 0001968582-23-000151 001-39941 23955060 33 4426
2023-05-24 144/A xsl144X01/primary_doc.xml 0001968582-23-000150 001-39941 23954865 33 4663
2023-05-24 144 xsl144X01/primary_doc.xml 0001968582-23-000149 001-39941 23952663 33 4435
2023-05-08 S-8 S-8 0001193125-23-138359 333-271728 23898637 33 98871
2023-05-08 10-Q 10-Q 0001564590-23-007074 001-39941 23898285 34 13344245 1 1
2023-05-08 8-K 8-K 2.02,9.01 0001564590-23-007072 001-39941 23898158 34 461387 1 1
2023-05-01 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-23-072746,2023-05-01 9999999995-23-001167 333-266547 23876423 33 1727
2023-05-01 POS EX POS EX 0001193125-23-130383 333-266547 23873567 33 56417
2023-04-28 8-K 8-K - AGARWAL TRANSITION AGREEMENT 5.02 0001564590-23-006600 001-39941 23866008 34 170973 1 1
2023-04-28 ARS ARS 0001193125-23-123985 001-39941 23859968 34 5453737
2023-04-28 DEFA14A DEFA14A 0001193125-23-123978 001-39941 23859958 34 380267
2023-04-28 DEF 14A DEF 14A 0001193125-23-123965 001-39941 23859919 34 1193614
2023-04-26 SC 13G filing.txt 0000315066-23-002246 005-92124 23846875 34 7755
2023-04-11 4 PRIMARY DOCUMENT 0001562180-23-003514 9109
2023-04-11 3 PRIMARY DOCUMENT 0001562180-23-003513 6769
2023-04-10 8-K 8-K - MANAGEMENT CHANGES 5.02,7.01,9.01 0001564590-23-005548 001-39941 23811297 34 211083 1 1
2023-04-06 4 PRIMARY DOCUMENT 0001562180-23-003475 8782
2023-04-06 4 PRIMARY DOCUMENT 0001562180-23-003474 8842
2023-03-16 POS AM POS AM 0001193125-23-072746 333-266547 23739802 33 962454
2023-03-16 10-K 10-K 0001564590-23-003798 001-39941 23739162 34 37248162 1 1
2023-03-16 8-K 8-K 2.02,9.01 0001564590-23-003795 001-39941 23738975 34 676642 1 1
2023-03-15 POSASR POSASR 0001193125-23-071344 333-266547 23735457 33 996027
2023-03-03 4 PRIMARY DOCUMENT 0001562180-23-002398 9406
2023-03-03 4 PRIMARY DOCUMENT 0001562180-23-002397 9318
2023-03-03 4 PRIMARY DOCUMENT 0001562180-23-002396 5472
2023-03-03 4 PRIMARY DOCUMENT 0001562180-23-002395 9377
2023-03-03 4 PRIMARY DOCUMENT 0001562180-23-002394 9387
2023-02-17 4 PRIMARY DOCUMENT 0001562180-23-001518 4645
2023-02-13 SC 13G/A ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G/A(#1) 0001072613-23-000103 005-92124 23618392 34 475702
2023-02-09 SC 13G/A filing.txt 0000315066-23-001347 005-92124 23601213 34 7946
2023-01-26 8-K 8-K- IND 8.01,9.01 0001564590-23-000832 001-39941 23557943 34 191804 1 1
2023-01-26 8-K 8-K 8.01,9.01 0001193125-23-016245 001-39941 23557909 34 166361 1 1
2023-01-20 SC 13G/A sanabiotechnology30122022.txt 0001088875-23-000035 005-92124 23538907 34 11144
2023-01-10 8-K 8-K 7.01,9.01 0001564590-23-000306 001-39941 23519787 34 10874882 1 1
2023-01-06 4 PRIMARY DOCUMENT 0001562180-23-000268 11755
2023-01-06 4 PRIMARY DOCUMENT 0001562180-23-000267 4731
2022-11-29 8-K 8-K 2.05,9.01 0001193125-22-294309 001-39941 221432904 34 177454 1 1
2022-11-02 10-Q 10-Q 0001564590-22-036375 001-39941 221354333 34 13571585 1 1
2022-11-02 8-K 8-K 2.02,9.01 0001564590-22-036367 001-39941 221354160 34 590851 1 1
2022-11-01 8-K 8-K - AMENDED CODE OF CONDUCT 5.05 0001564590-22-036057 001-39941 221350215 34 167356 1 1
2022-10-06 4 PRIMARY DOCUMENT 0001562180-22-007110 11755
2022-10-06 4 PRIMARY DOCUMENT 0001562180-22-007109 4732
2022-09-20 3/A FORM 3/A SUBMISSION 0000899243-22-031582 3972
2022-09-16 4 PRIMARY DOCUMENT 0001562180-22-006711 5512
2022-09-16 3 PRIMARY DOCUMENT 0001562180-22-006710 7056
2022-08-04 S-3ASR S-3ASR 0001193125-22-212687 333-266547 221137853 33 1304670
2022-08-04 10-Q 10-Q 0001564590-22-028036 001-39941 221137545 34 13844459 1 1
2022-08-04 8-K 8-K 2.02,9.01 0001564590-22-028027 001-39941 221137332 34 596393 1 1
2022-07-07 4 PRIMARY DOCUMENT 0001562180-22-005623 4736
2022-07-07 4 PRIMARY DOCUMENT 0001562180-22-005622 11760
2022-06-15 4 PRIMARY DOCUMENT 0001562180-22-005121 11348
2022-06-14 8-K 8-K 7.01,9.01 0001564590-22-023139 001-39941 221013536 34 10349509 1 1
2022-06-09 8-K 8-K 5.07 0001193125-22-171023 001-39941 221006002 34 154541 1 1
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004946 5536
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004945 5571
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004944 5565
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004943 5624
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004942 5544
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004941 5578
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004940 5524
2022-06-08 4 PRIMARY DOCUMENT 0001562180-22-004939 5530
2022-06-01 8-K 8-K 1.01,2.03,8.01,9.01 0001193125-22-165186 001-39941 22987484 34 175668 1 1
2022-05-19 SC 13G filing.txt 0000315066-22-001587 005-92124 22941205 34 7539
2022-05-10 S-8 REGISTRATION STATEMENT ON FORM S-8 0001193125-22-146418 333-264846 22910856 33 105730
2022-05-10 10-Q 10-Q 0001564590-22-019299 001-39941 22910121 34 11202522 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001564590-22-019286 001-39941 22909917 34 414876 1 1
2022-04-26 DEFA14A DEFA14A 0001193125-22-118708 001-39941 22851665 34 433511
2022-04-26 DEF 14A DEF 14A 0001193125-22-118701 001-39941 22851654 34 919577
2022-04-15 4 PRIMARY DOCUMENT 0001562180-22-003413 8922
2022-04-06 4 PRIMARY DOCUMENT 0001562180-22-003313 4735
2022-04-06 4 PRIMARY DOCUMENT 0001562180-22-003312 11759
2022-03-22 4 PRIMARY DOCUMENT 0001562180-22-002871 5241
2022-03-16 10-K 10-K 0001564590-22-010539 001-39941 22743422 34 54809015 1 1
2022-03-16 8-K 8-K 2.02,9.01 0001564590-22-010538 001-39941 22743411 34 664421 1 1
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002430 5445
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002429 5453
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002428 5487
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002427 5511
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002426 5477
2022-03-08 4 PRIMARY DOCUMENT 0001562180-22-002425 5503
2022-02-23 4 PRIMARY DOCUMENT 0001562180-22-001784 9181
2022-02-14 SC 13G SC 13G 0001104659-22-023026 005-92124 22633746 34 46907
2022-02-14 SC 13G SC 13G 0001193125-22-041281 005-92124 22630099 34 178412
2022-02-10 SC 13G ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G 0001072613-22-000080 005-92124 22615269 34 458728
2022-02-09 SC 13G/A filing.txt 0000315066-22-001310 005-92124 22604795 34 8258
2022-01-26 SC 13G sanabiotechnology31122021.txt 0001088875-22-000044 005-92124 22555671 34 11125
2022-01-11 8-K 8-K - NIH AND JPM 1.01,7.01,8.01,9.01 0001564590-22-000913 001-39941 22522660 34 9904770 1 1
2021-11-08 10-Q 10-Q 0001564590-21-055263 001-39941 211388298 34 13155537 1 1
2021-11-08 8-K 8-K 2.02,9.01 0001564590-21-055251 001-39941 211388078 34 607308 1 1
2021-10-19 8-K 8-K 1.01,8.01,9.01 0001564590-21-051086 001-39941 211329735 34 198705 1 1
2021-09-17 4 PRIMARY DOCUMENT 0001562180-21-005999 6946
2021-09-14 4 PRIMARY DOCUMENT 0001562180-21-005940 4894
2021-09-13 8-K 8-K 7.01,9.01 0001193125-21-271045 001-39941 211248856 34 16459767 1 1
2021-09-10 4 PRIMARY DOCUMENT 0001562180-21-005916 11150
2021-09-07 4 PRIMARY DOCUMENT 0001562180-21-005865 16299
2021-09-03 4 PRIMARY DOCUMENT 0001562180-21-005810 11146
2021-09-03 8-K 8-K (GEOFF RESIGNATION) 5.02 0001564590-21-047101 001-39941 211236610 34 166583 1 1
2021-09-01 4 PRIMARY DOCUMENT 0001562180-21-005697 11145
2021-08-04 10-Q 10-Q 0001564590-21-040861 001-39941 211144465 34 12734722 1 1
2021-08-04 8-K 8-K 2.02,9.01 0001564590-21-040845 001-39941 211144356 34 593206 1 1
2021-07-30 S-8 REGISTRATION STATEMENT ON FORM S-8 0001193125-21-231455 333-258302 211132596 33 248884
2021-07-14 8-K 8-K 1.01,2.03 0001564590-21-036569 001-39941 211090379 34 174618 1 1
2021-05-05 10-Q 10-Q 0001564590-21-024148 001-39941 21894048 34 10245332 1 1
2021-05-05 8-K 8-K 2.02,9.01 0001564590-21-024089 001-39941 21893609 34 266975
2021-04-27 4 FORM 4 SUBMISSION 0000899243-21-017134 10973
2021-03-24 10-K FORM 10-K 0001193125-21-092650 001-39941 21768458 34 9995321
2021-03-24 8-K 8-K 2.02,9.01 0001193125-21-092641 001-39941 21768417 34 134445
2021-03-02 8-K FORM 8-K 5.02 0001193125-21-065656 001-39941 21704775 34 35046
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007199 5654
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007197 5608
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007195 5620
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007194 5655
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007193 5708
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007191 5628
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007187 5615
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007185 5663
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007184 5649
2021-02-18 4/A FORM 4/A SUBMISSION 0000899243-21-007181 5756
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005753 42159
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005752 52374
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005749 11457
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005747 35933
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005739 37558
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005738 12243
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005736 11162
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005728 12642
2021-02-10 SC 13G filing.txt 0000315066-21-001392 005-92124 21609605 34 8040
2021-02-09 8-K 8-K 5.03,8.01,9.01 0001193125-21-032935 001-39941 21603789 34 214759
2021-02-08 S-8 S-8 0001193125-21-032543 333-252862 21602714 33 112438
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005086 5260
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005083 5299
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005082 5253
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005080 5401
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005076 5297
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005072 5273
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005071 5353
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005069 5272
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005067 5262
2021-02-05 4 FORM 4 SUBMISSION 0000899243-21-005065 5307
2021-02-05 424B4 PROSPECTUS FILED PURSUANT TO RULE 424(B)(4) 0001193125-21-029606 333-252061 21593317 33 11691039
2021-02-03 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-02-03 16:30:00 9999999995-21-000413 333-252061 21588696 33 1712
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004897 9938
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004886 31856
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004885 24072
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004882 8122
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004880 40632
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004876 9893
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004860 9197
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004858 7450
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004856 7933
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004853 13844
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004852 8054
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004847 9855
2021-02-03 S-1MEF S-1MEF 0001193125-21-027709 333-252706 21588460 33 84264
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004843 15096
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004819 24070
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004801 10879
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004800 9919
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004796 6630
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004793 8103
2021-02-03 CERT 8A_Cert_SANA.pdf 0001354457-21-000148 001-39941 21584744 34 302377
2021-02-03 S-1/A S-1/A 0001193125-21-026330 333-252061 21584105 33 11797780
2021-02-02 S-1/A S-1/A 0001193125-21-025048 333-252061 21578833 33 12308527
2021-02-01 CORRESP filename1.htm 0001193125-21-024542 21310
2021-01-28 CORRESP filename1.htm 0001193125-21-019993 37887
2021-01-28 S-1/A AMENDMENT NO. 1 TO FORM S-1 0001193125-21-019984 333-252061 21562064 33 13104093
2021-01-25 8-A12B 8-A12B 0001193125-21-016261 001-39941 21549861 34 13890
2021-01-25 UPLOAD filename1.pdf 0000000000-21-000841 44122
2021-01-20 CORRESP filename1.htm 0001193125-21-012702 116062
2021-01-13 S-1 REGISTRATION STATEMENT ON FORM S-1 0001193125-21-007483 333-252061 21524722 33 16333478
2021-01-12 CORRESP filename1.htm 0001193125-21-007488 31749
2021-01-04 UPLOAD filename1.pdf 0000000000-21-000031 44874
2020-12-18 DRSLTR filename1.htm 0000950123-20-012754 70637
2020-12-18 DRS/A filename1.htm 0000950123-20-012753 377-03768 201401691 33 13532772
2020-12-08 UPLOAD filename1.pdf 0000000000-20-011736 66006
2020-11-10 DRS filename1.htm 0000950123-20-011218 377-03768 201302251 33 10655565
2020-06-26 D xslFormDX01/primary_doc.xml 06b 0001770121-20-000003 021-369787 20993075 33 15496
2020-06-26 D xslFormDX01/primary_doc.xml 06b 0001770121-20-000002 021-369781 20992930 33 15468

Latest XBRL company facts

One latest value per concept from companyfacts (220 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 299.63M 2026-10-29 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
dei EntityPublicFloat Entity Public Float USD 295.10M 2025-06-30 2025 FY 10-K 2026-03-03 0001193125-26-088215
ffd NetFeeAmt NetFeeAmt USD 6,151.55 2026-05-08 S-8 2026-05-11 0001193125-26-216824
ffd NrrtvMaxAggtOfferingPric NrrtvMaxAggtOfferingPric USD 50.00M 2026-04-13 424B5 2026-04-13 0001193125-26-153046
ffd TtlFeeAmt TtlFeeAmt USD 6,151.55 2026-05-08 S-8 2026-05-11 0001193125-26-216824
ffd TtlOfferingAmt TtlOfferingAmt USD 44.54M 2026-05-08 S-8 2026-05-11 0001193125-26-216824
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-05-08 S-8 2026-05-11 0001193125-26-216824
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-04-13 424B5 2026-04-13 0001193125-26-153046
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.95M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccruedBonusesCurrent Accrued Bonuses, Current USD 6.31M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 8.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.84M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 1.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 2.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 62.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -104,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 2.12B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 5.33M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 3.69M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 9,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 16.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 32.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap Assets Assets USD 376.13M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap AssetsCurrent Assets, Current USD 132.31M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability USD -28.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability USD 44.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap BusinessCombinationContingentConsiderationLiabilityCurrent Business Combination, Contingent Consideration, Liability, Current USD 40.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap BusinessCombinationContingentConsiderationLiabilityNoncurrent Business Combination, Contingent Consideration, Liability, Noncurrent USD 54.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 41.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 44.87M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -31.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 750.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 299.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 299.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap CommonStockValue Common Stock, Value, Issued USD 30,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -90.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 134.10M 2021-02-28 2021 Q3 10-Q 2021-11-08 0001564590-21-055263
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 10.39M 2023-12-31 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss USD 75,000 2023-12-31 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions security 34 2022-09-30 2022 Q3 10-Q 2022-11-02 0001564590-22-036375
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 9.13M 2024-09-30 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss USD 1,000 2024-09-30 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-02 0001564590-22-036375
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 9.13M 2024-09-30 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 1,000 2024-09-30 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap DeferredCompensationCashbasedArrangementsLiabilityCurrentAndNoncurrent Deferred Compensation Cash-based Arrangements, Liability, Current and Noncurrent USD 5.80M 2024-12-31 2024 FY 10-K 2025-03-17 0000950170-25-040254
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -7.55M 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 73.89M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 6.88M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 517.64M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 9.83M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 299.76M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 245.20M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 73.60M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 401,000 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 12.34M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 88.71M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 4.09M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 507.81M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 24.71M 2022-12-31 2022 FY 10-K 2023-03-16 0001564590-23-003798
us-gaap DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Deferred Tax Liabilities, Intangible Assets USD 6.87M 2020-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 49,000 2021-12-31 2022 FY 10-K 2023-03-16 0001564590-23-003798
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 1.16M 2022-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap Depreciation Depreciation USD 7.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.31 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.17 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019299
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.31 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.181 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.004 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.022 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.063 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.013 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.038 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.021 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 10.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap FacilityCosts Facility Costs USD 32.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 33.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap Goodwill Goodwill USD 140.63M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0001564590-21-055263
us-gaap ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) USD 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -355.93M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 44.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -51.27M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 908,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.43M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 95,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 3.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 5.22M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 154,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -4.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -12.00M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -1.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 59.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 3.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap InvestmentsAndCash Investments and Cash USD 121.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LeaseCost Lease, Cost USD 22.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 85.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 16.45M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 7.76M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 5.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 7.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 9.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 5.66M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 31.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap Liabilities Liabilities USD 195.76M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 376.13M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap LiabilitiesCurrent Liabilities, Current USD 74.88M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 80.62M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 10.05M 2022-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -2.96M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0001564590-23-003798
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 93.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -15.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -108.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -90.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -90.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -217.69M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-08 0000950170-24-123730
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingExpenses Operating Expenses USD 95.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -95.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseCost Operating Lease, Cost USD 13.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 53.84M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 13.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 40.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 20.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 8.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.114 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 2.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 551,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -38,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -132,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherEmployeeRelatedLiabilitiesCurrent Other Employee-related Liabilities, Current USD 24,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0001564590-21-055263
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 9.08M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 7.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 1.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PaymentsForProceedsFromOtherInvestingActivities Payments for (Proceeds from) Other Investing Activities USD 4.57M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap PaymentsForTenantImprovements Payments for Tenant Improvements USD 5.45M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 96,000 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-11 0001193125-26-216769
us-gaap PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired USD 3.19M 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 123.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 2.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 50.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 6.82M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 626.40M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 89.62M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 435.54M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-16 0001564590-23-003798
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 421,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 110.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 316,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 2.23M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-08 0001564590-21-055263
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -90.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 85.14M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 23.11M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 93.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap RestrictedCash Restricted Cash USD 3.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 4.20M 2025-12-31 2025 FY 10-K 2026-03-03 0001193125-26-088215
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 4.41M 2022-12-31 2024 FY 10-K 2025-03-17 0000950170-25-040254
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 3.76M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 4.41M 2022-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.94B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 2.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD 7.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 16.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.75 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.9 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.775 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.051 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.037 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 17.14M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 6.35 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 217,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 1.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 7.62 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 6.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.42 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 28.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 5.45 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 2.48M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 3.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 2.01 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 3.42 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 4 2019-03-31 2022 Q3 10-Q 2022-11-02 0001564590-22-036375
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 2.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 180.36M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.25 2021-01-01 2021-01-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap StockIssuedDuringPeriodSharesAcquisitions Stock Issued During Period, Shares, Acquisitions shares 12.10M 2019-07-01 2019-07-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 117,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 852.90M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023119
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 186,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 89.75M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 1,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-17 0000950170-25-040254
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 117,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 852.90M 2020-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 0 2021-06-30 2021 Q2 10-Q 2021-08-04 0001564590-21-040861
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2021-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues Temporary Equity, Stock Issued During Period, Value, New Issues USD 435.54M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-16 0001564590-22-010539
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic USD 749,000 2021-04-01 2021-06-30 2022 Q2 10-Q 2022-08-04 0001564590-22-028036
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted USD 749,000 2021-04-01 2021-06-30 2022 Q2 10-Q 2022-08-04 0001564590-22-028036
us-gaap VariableLeaseCost Variable Lease, Cost USD 6.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 293.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 185.96M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0001564590-22-019299
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 293.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449836

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →